LQDA vs. MNKD, HRTX, PDEX, DRIO, XAIR, PRGO, CRNX, AXSM, CORT, and HCM
Should you be buying Liquidia stock or one of its competitors? The main competitors of Liquidia include MannKind (MNKD), Heron Therapeutics (HRTX), Pro-Dex (PDEX), DarioHealth (DRIO), Beyond Air (XAIR), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), Axsome Therapeutics (AXSM), Corcept Therapeutics (CORT), and HUTCHMED (HCM). These companies are all part of the "medical" sector.
MannKind (NASDAQ:MNKD) and Liquidia (NASDAQ:LQDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends.
MannKind has a net margin of 3.78% compared to MannKind's net margin of -674.42%. Liquidia's return on equity of -3.35% beat MannKind's return on equity.
In the previous week, MannKind had 1 more articles in the media than Liquidia. MarketBeat recorded 5 mentions for MannKind and 4 mentions for Liquidia. MannKind's average media sentiment score of 1.12 beat Liquidia's score of 0.77 indicating that Liquidia is being referred to more favorably in the news media.
MannKind received 388 more outperform votes than Liquidia when rated by MarketBeat users. However, 66.55% of users gave Liquidia an outperform vote while only 59.87% of users gave MannKind an outperform vote.
MannKind has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.
MannKind presently has a consensus price target of $8.00, indicating a potential upside of 71.31%. Liquidia has a consensus price target of $21.00, indicating a potential upside of 63.17%. Given Liquidia's stronger consensus rating and higher probable upside, equities research analysts plainly believe MannKind is more favorable than Liquidia.
49.6% of MannKind shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 3.0% of MannKind shares are held by company insiders. Comparatively, 31.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
MannKind has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.
Summary
MannKind beats Liquidia on 12 of the 18 factors compared between the two stocks.
Get Liquidia News Delivered to You Automatically
Sign up to receive the latest news and ratings for LQDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LQDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Liquidia Competitors List
Related Companies and Tools
